脂质体gp100脉冲树突状细胞疫苗增强抗PD-1治疗黑色素瘤小鼠模型疗效
该研究在小鼠B16F10黑色素瘤模型中,将gp10025-33抗原装饰的脂质体体外脉冲树突状细胞(DC)后联合抗PD-1治疗,观察到最强的抗癌免疫、瘤内gp100特异性CD4+和CD8+ T细胞浸润增加、显著肿瘤消退和生存期延长,并增强脾脏CTL反应和IFN-γ滴度。
要点
- 脂质体gp100脉冲DC疫苗联合抗PD-1可显著抑制肿瘤生长并延长生存。
- 该疫苗增强瘤内gp100特异性CD4+和CD8+ T细胞浸润及脾脏CTL反应。
- 联合治疗后瘤内PD-1表达CD8+肿瘤浸润淋巴细胞显著增加。
核心结论
- 脂质体gp100脉冲DC疫苗联合抗PD-1治疗在小鼠黑色素瘤模型中增强抗肿瘤免疫并改善疗效。
研究设计与样本
- 小鼠B16F10 established黑色素瘤肿瘤模型,皮下注射脂质体gp100脉冲的DC联合抗PD-1治疗。
主要发现
- 治疗引发最强抗癌免疫,基于gp100特异性CD4+和CD8+ T细胞浸润至肿瘤,导致显著肿瘤生长消退和生存率延长。
- 治疗显著增强特异性细胞毒性T淋巴细胞(CTL)反应,脾脏IFN-γ滴度显著更高。
- 肿瘤中检测到PD-1表达CD8+肿瘤浸润淋巴细胞(TILs)显著增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Targeting antigens to dendritic cells (DCs) via nanoparticles is a powerful strategy which improves the efficacy of ex vivo antigen-pulsed DC vaccines. METHODS: In this study, liposomes were first decorated with gp10025-33 self-antigen and then characterized. Then, DCs were pulsed ex vivo with liposomal gp100 and injected subcutaneously in mice bearing B16F10 established melanoma tumors in combination with anti-PD-1 therapy. RESULTS: Treatment with liposomal pulsed DC vaccine elicited the strongest anticancer immunity and enhanced intratumoral immune responses based on infiltration of gp100-specific CD4+ and CD8+ T cells to the tumor leading to significant tumor growth regression and prolonged survival rate. Treatment with liposomal pulsed DC vaccine also markedly enhanced specific cytotoxic T lymphocytes (CTL) responses with a significant higher titer of IFN-γ in the spleen. Moreover, a significant increase of PD-1 expressing CD8+ tumor infiltrating lymphocytes (TILs) was detected in tumors. CONCLUSION: Our results demonstrate an optimum dose of liposomal gp100 significantly increases the efficacy of anti-PD-1 therapy in mice and might be an effective strategy to overcome resistance to anti-PD-1 therapy.
引用
- Yazdani M, Gholizadeh Z, Nikpoor AR, et al. Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma. Vaccine. 2020. PMID: 32653275. doi:10.1016/j.vaccine.2020.06.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。